161 related articles for article (PubMed ID: 18665340)
1. [ Therapy of patients at high risk for vascular events: telmisartan, ramipril or a combination? ].
Düsing R; Nitschmann S
Internist (Berl); 2008 Sep; 49(9):1137-40. PubMed ID: 18665340
[No Abstract] [Full Text] [Related]
2. Telmisartan, ramipril, or both in patients at high risk of vascular events.
Messerli FH; Bangalore S; Ram VS
N Engl J Med; 2008 Jul; 359(4):426-7; author reply 427. PubMed ID: 18655247
[No Abstract] [Full Text] [Related]
3. Telmisartan, ramipril, or both in patients at high risk for vascular events.
; Yusuf S; Teo KK; Pogue J; Dyal L; Copland I; Schumacher H; Dagenais G; Sleight P; Anderson C
N Engl J Med; 2008 Apr; 358(15):1547-59. PubMed ID: 18378520
[TBL] [Abstract][Full Text] [Related]
4. Proteinuria: Is the ONTARGET renal substudy actually off target?
Ruggenenti P; Remuzzi G
Nat Rev Nephrol; 2009 Aug; 5(8):436-7. PubMed ID: 19639016
[No Abstract] [Full Text] [Related]
5. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.
Mann JF; Schmieder RE; McQueen M; Dyal L; Schumacher H; Pogue J; Wang X; Maggioni A; Budaj A; Chaithiraphan S; Dickstein K; Keltai M; Metsärinne K; Oto A; Parkhomenko A; Piegas LS; Svendsen TL; Teo KK; Yusuf S;
Lancet; 2008 Aug; 372(9638):547-53. PubMed ID: 18707986
[TBL] [Abstract][Full Text] [Related]
6. Telmisartan prevents cardiovascular events in a broad group of at-risk patients.
Baumhäkel M; Böhm M
Expert Opin Pharmacother; 2009 Dec; 10(18):3113-7. PubMed ID: 19925045
[TBL] [Abstract][Full Text] [Related]
7. Telmisartan and stroke reduction in the ONTARGET trial: benefit beyond blood pressure lowering?
Serebruany VL; Atar D; Hanley DF
Cerebrovasc Dis; 2008; 26(5):563-4. PubMed ID: 18936537
[No Abstract] [Full Text] [Related]
8. Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes.
Clase CM; Barzilay J; Gao P; Smyth A; Schmieder RE; Tobe S; Teo KK; Yusuf S; Mann JF
Kidney Int; 2017 Mar; 91(3):683-690. PubMed ID: 27927602
[TBL] [Abstract][Full Text] [Related]
9. ONTARGET should not be over interpreted.
Abutaleb N
Nephrol Dial Transplant; 2010 Jan; 25(1):44-7. PubMed ID: 19934088
[No Abstract] [Full Text] [Related]
10. Telmisartan, ramipril, or both in patients at high risk of vascular events.
Büchner N; Banas B; Krämer BK
N Engl J Med; 2008 Jul; 359(4):426. PubMed ID: 18650521
[No Abstract] [Full Text] [Related]
11. Is therapy of people with chronic kidney disease ONTARGET?
Mann JF; Tobe S; Teo KK; Yusuf S
Nephrol Dial Transplant; 2010 Jan; 25(1):42-4. PubMed ID: 19854846
[No Abstract] [Full Text] [Related]
12. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies.
Anderson C; Teo K; Gao P; Arima H; Dans A; Unger T; Commerford P; Dyal L; Schumacher H; Pogue J; Paolasso E; Holwerda N; Chazova I; Binbrek A; Young J; Yusuf S;
Lancet Neurol; 2011 Jan; 10(1):43-53. PubMed ID: 20980201
[TBL] [Abstract][Full Text] [Related]
13. [Critically appraised article].
Neumann I; Grassi B
Rev Med Chil; 2012 Jan; 140(1):117-20. PubMed ID: 22552566
[TBL] [Abstract][Full Text] [Related]
14. Antihypertensive efficacy of telmisartan vs ramipril over the 24-h dosing period, including the critical early morning hours: a pooled analysis of the PRISMA I and II randomized trials.
Williams B; Lacourcière Y; Schumacher H; Gosse P; Neutel JM
J Hum Hypertens; 2009 Sep; 23(9):610-9. PubMed ID: 19225530
[TBL] [Abstract][Full Text] [Related]
15. Telmisartan, ramipril, or both in high-risk Chinese patients: analysis of ONTARGET China data.
Yu LT; Zhu J; Tan HQ; Wang GG; Teo KK; Liu LS
Chin Med J (Engl); 2011 Jun; 124(12):1763-8. PubMed ID: 21740829
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of fixed dose combination (FDC) of telmisartan+ramipril usage in patients with micro-albuminuria and persistent hypertension: A TRIUMPH study.
Sharma A; Baliga V;
J Indian Med Assoc; 2008 Mar; 106(3):191-4, 196. PubMed ID: 18712142
[TBL] [Abstract][Full Text] [Related]
17. New data on ONTARGET: more confusion?
Escobar C; Echarri R; Barrios V
J Clin Hypertens (Greenwich); 2010 Mar; 12(3):199. PubMed ID: 20433538
[No Abstract] [Full Text] [Related]
18. ONTARGET, TRANSCEND and PROFESS--clarifying, confusing or misleading?
Oparil S; Kjeldsen SE; Hedner T; Narkiewicz K
Blood Press; 2009; 18(1-2):4-6. PubMed ID: 19191085
[No Abstract] [Full Text] [Related]
19. ONTARGET: questions asked, questions answered.
Weber MA
J Clin Hypertens (Greenwich); 2008 Jun; 10(6):427-30. PubMed ID: 18550931
[No Abstract] [Full Text] [Related]
20. The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.
Heerspink HJ; Gao P; de Zeeuw D; Clase C; Dagenais GR; Sleight P; Lonn E; Teo KT; Yusuf S; Mann JF
Eur J Prev Cardiol; 2014 Mar; 21(3):299-309. PubMed ID: 24191305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]